–
enGene Therapeutics Inc.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
millions USD
FY21:
FY22:
–
FY23:
–
FY24:
–
FY25:
–
(positive)
Change from FY21 to FY25
millions USD
FY21:
−15.9
FY22:
−19.4
FY23:
−26.1
FY24:
−62.3
FY25:
−123
(positive)
Change from FY21 to FY25
millions USD
FY21:
−15.7
FY22:
−19.7
FY23:
−81.1
FY24:
−51.7
FY25:
−114
(positive)
Change from FY21 to FY25
millions USD
FY21:
−23.4
FY22:
−24.4
FY23:
−99.9
FY24:
−55.2
FY25:
−117
(positive)
Change from FY21 to FY25
millions USD
FY21:
−23.4
FY22:
−24.5
FY23:
−99.9
FY24:
−55.1
FY25:
−117
All amounts in millions USD FY21: figures supplemented from Twelve Data because the SEC filings do not reach back this far.